JPM vs LMFA
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
JPM exhibits a concerning Piotroski F-Score of 2/9, indicating weak short-term fundamental health, and currently trades at a significant premium to both its Graham Number ($239.11) and Intrinsic Value ($140.07). While the company maintains a strong ROE of 16.13% and dominant market positioning, negative YoY earnings growth (-3.60%) and bearish insider activity from the CEO and CFO signal internal caution. The stock's current price of $313.68 suggests the market is pricing in a growth premium that is not currently supported by the deterministic health or value metrics.
LMFA is in a state of severe financial distress, evidenced by a critical Piotroski F-Score of 1/9. The company exhibits catastrophic operational inefficiency with an operating margin of -494.61% and a near-total lack of liquid assets, as shown by a Quick Ratio of 0.08. While the Price-to-Book ratio of 0.13 suggests a deep discount, the consistent earnings misses and a 99.2% decline in value over five years indicate a classic value trap. The single analyst 'Buy' rating is fundamentally unsupported by the current trajectory of the business.
Compare Another Pair
Related Comparisons
JPM vs LMFA: Head-to-Head Comparison
This page compares JPMorgan Chase & Co. (JPM) and LM Funding America, Inc. (LMFA) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.